HIV Subtypes Distribution and Implication for Antiretroviral Treatment in a Ugandan Population

Kaleebu P. , Ross A. , Morgan D. , et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS. 2001;15(3):293-299.

Kaleebu P. , French N. , Mahe C. , et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis. 2002;185(9):1244-1250.

Richard N. , Juntilla M. , Abraha A. , et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2004;20(4):355-364.

Nijhuis M. , Schuurman R. , de Jong D. , et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999;13(17):2349-2359.

Erickson JW , Gulnik SV , Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS. 1999 ;13(Suppl A):S189-S204.

Vergne L. , Peeters M. , Mpoudi-Ngole E. , et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38(11):3919-3925.

Solomon A. , Cameron PU , Bailey M. , et al. Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. J Infect Dis. 2003;187(12):1915 -1923.

Hazenberg MD , Otto SA , van Benthem BH , et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17(13):1881-1888.

Liu Z. , Cumberland WG , Hultin LE , Prince HE , Detels R. , Giorgi JV Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(2):83-92.

Giorgi JV , Hultin LE , McKeating JA , et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859-870.

Bruce C. , Clegg JC , Featherstone A. , et al. Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda. AIDS Res Hum Retroviruses . 1994;10: 1543-1550.

Hoelscher M. , Dowling WE , Sanders-Buell E. , et al. Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay. AIDS. 2002;16:2055-2064.

Hu DJ , Dondero TJ , Rayfield MA , et al. The emerging genetic diversity of HIV: the importance of global surveillance for diagnostics, research and prevention. JAMA. 1996;275:210-216.

Eggena MP , Barugahare B. , Okello M. , et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis. 2005;191(5):694-701.

Barugahare B. , Baker C. , K'Aluoch O. , et al. Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition. J Virol. 2005;79(7):4132-4139.

Rizzardini G. , Piconi S. , Ruzzante S. , et al. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals . AIDS. 1996; 10(13):1535-1542.

Eggena MP , Barugahare B. , Jones N. , et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005;174(7):4407-4414.

Kantor R. , Katzenstein DA , Efron B. , et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2(4):e112.

Spira S. , Wainberg MA , Loemba H. , Turner D. , Brenner BG Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003;51(2):229-240.

Weidle PJ , Malamba S. , Mwebaze R. , et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360(9326): 34-40.

Palmer S. , Margot N. , Gilbert H. , Shaw N. , Buckheit R. Jr , Miller M. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses. 2001;17(12):1167-1173.

Dumans AT , Soares MA , Machado ES , et al. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis. 2004;189(7):1232-1238.

Frater J. The impact of HIV-1 subtype on the clinical response on HAART. J HIV Ther. 2002;7(4):92-96.

Loemba H. , Brenner B. , Parniak MA , et al. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res. 2002;56(2):129-142.

Katzenstein TL Molecular biological assessment methods and understanding the course of the HIV infection. APMIS Suppl . 2003(114):1-37.

Hazenberg MD , Otto SA , Wit FW , Lange JM , Hamann D. , Miedema F. Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss. AIDS. 2002;16(9):1287-1289.

Sufka S. , Ferrari G. , Gryszowka V. , et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis. 2003;187:1027-1037.